Clinical trials: Hypoglycemic Syndrome
Type 1 Diabetes Mellitus
Feasibility Study Assessing The Ability Of An Insulin Pump-Controlling Algorithm To Minimize Hypoglycemia And Hyperglycemia In Patients With Type 1 Diabetes In A Clinical Research Setting
The purpose of this study is to evaluate the performance of an insulin pump controlling algorithm while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.
- Trial name
- NCT01401751
- Testing
- Hypoglycemia-Hyperglycemia Minimizer System
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
Type 1 Diabetes Mellitus
Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting
Feasibility study assessing the ability of an insulin pump-controlling algorithm to minimize hypoglycemia and hyperglycemia in patients with type 1 diabetes in a clinical research setting.
- Trial name
- NCT01638299
- Testing
- Hypo-Hyper Minimizer (HHM) System
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
Diabetes, Diabetes Mellitus, Type 2
A Trial to Investigate the Impact of Nocturnal Hypoglycaemia on Sleep in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the impact of low blood sugar during the night on sleep in subjects with type 2 diabetes.
- Trial name
- NCT01780272
- Testing
- glucose clamp
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus With Hypoglycemia
A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness
VC02-101 will evaluate an experimental cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes and Hypoglycemia Unawareness.
- Trial name
- NCT03163511
- Testing
- VC-02 Combination Product
- Where
- 10 sites in United States, Belgium and 1 more
- Volunteers
- 49 people
- Sponsor
- ViaCyte
Post Bariatric Hypoglycemia
Avexitide for Treatment of Post-Bariatric Hypoglycemia
AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB).
- Trial name
- LUCIDITY (NCT06747468)
- Testing
- Avexitide
- Where
- 21 sites in United States
- Volunteers
- 75 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Hypoglycemia
An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery
The purpose of this study is to evaluate the safety and clinical pharmacology of XOMA 358 in patients with hypoglycemia after gastric bypass surgery.
- Trial name
- XOMA 358 (NCT02772718)
- Testing
- XOMA 358 single dose level A, XOMA 358 single dose level B, XOMA 358 single dose level C
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- XOMA (US) LLC
Type 2 Diabetes Mellitus (T2DM)
Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)
This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.
- Trial name
- NCT01131182
- Testing
- Sitagliptin phosphate, Comparator: Sulfonylurea, Metformin
- Volunteers
- 1,147 people
- Sponsor
- Merck Sharp & Dohme LLC
Postbariatric Hypoglycemia
Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects
This clinical study will examine the safety and tolerability, as well as the effects of orally administered mizagliflozin on post prandial glucose and insulin levels in subjects diagnosed with post-bariatric hypoglycemia (PBH).
- Trial name
- NCT05541939
- Testing
- Mizagliflozin
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Vogenx, Inc.
Hypoglycemia, Diabetes Mellitus, Type 1
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo
- Trial name
- NCT03688711
- Testing
- Dasiglucagon
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Zealand Pharma
Insulin Hypoglycemia, Type 1 Diabetes Mellitus
G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes
This is a non-inferiority, multi-center, randomized, controlled, single-blind, two-way crossover efficacy and safety study in subjects with Type 1 diabetes mellitus.
- Conditions
- Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
- Trial name
- NCT03439072
- Testing
- G-Pen, Lilly Glucagon
- Where
- 6 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- Xeris Pharmaceuticals
Insulin Hypoglycemia, Type 1 Diabetes Mellitus
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
This is a multi-center, randomized, controlled, single-blind, two-way crossover efficacy and safety study in subjects with Type 1 diabetes mellitus.
- Conditions
- Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
- Trial name
- NCT03738865
- Testing
- G-Pen, Novo Glucagon
- Where
- 7 sites in United States, Austria and 1 more
- Volunteers
- 132 people
- Sponsor
- Xeris Pharmaceuticals
Post-bariatric Hypoglycemia
An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia
The Expanded Access Program will provide access to avexitide for people with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) who meet the eligibility criteria for this program.
- Trial name
- NCT07582874
- Testing
- Avexitide
- Where
- 4 sites in United States
- Sponsor
- Amylyx Pharmaceuticals Inc.
Diabetes Mellitus, Type 1, Hypoglycemia
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
This study is First In Human study for Encapsulated Porcine Islet Cells for Xenotransplantation (OPF-310). The purpose of this study to assess the safety, tolerability, and efficacy of OPF-310 transplantation and to define the…
- Conditions
- Diabetes Mellitus, Type 1, Hypoglycemia, Islet Cell Transplantation, Type 1 Diabetes
- Trial name
- NCT06575426
- Testing
- OPF-310
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Otsuka Pharmaceutical Factory, Inc.
Type 2 Diabetes Mellitus, Elderly
Phase 4 Study in the Elderly Patients With T2DM
The study will assess the incidence of Hypoglycemia: Percent of patients presenting no hypoglycemia (confirmed events with SMBG and severe episodes) over 6 months follow up in T2DM patients treated with a DPP-4 inhibitor or…
- Trial name
- GLYCEMIA (NCT01238978)
- Testing
- Vildagliptin, "Usual Care"
- Where
- 15 sites in France
- Volunteers
- 46 people
- Sponsor
- Novartis
Diabetes Mellitus
The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing
To compare the percentage of subjects with a glucose measurement < than or = to 56 mg/dL at any point of the 8-point glucose profiles during 3 consecutive days before vs.
- Trial name
- NCT00609895
- Testing
- INSULIN GLARGINE
- Where
- Mexico
- Volunteers
- 22 people
- Sponsor
- Sanofi
Sugar; Blood, Low
ENSO 16 - Study in Healthy Subjects
The objective of this study is to evaluate differences in glucose metabolism parameters after oral administration of 30g glucose or 30g ENSO16.
- Trial name
- NCT05457400
- Testing
- ENSO 16, Glucose Powder
- Where
- Austria
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Alpha Republic GmbH
Diabetes Mellitus, Type 1
The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France
This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use…
- Trial name
- RECORD-IQ (NCT07211126)
- Testing
- t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)
- Where
- 25 sites in France
- Volunteers
- 350 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia
Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes
First in Human, pilot investigation An Open Label, Monocentric, Pilot Study Evaluating Safety of ExOlin® in Patients with Poorly Controlled Type 1 Diabetes with High Glucose Fluctuations, Prone to Severe Hypoglycemia
- Trial name
- Pilot'Ex (NCT05221359)
- Testing
- ExOlin®, Insulin aspart
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Defymed
Type 2 Diabetes Mellitus
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
The purpose of this study is to measure the effect of retatrutide versus placebo, administered every week, on time to recovery from hypoglycemia during hypoglycemic clamp in participants with Type 2 Diabetes Mellitus (T2DM)…
- Trial name
- NCT06982846
- Testing
- Retatrutide
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Prevention of Severe Hypoglycaemia With Hypo-Safe Hypoglycaemia Alarm Device
Hypoglycaemia is the most common acute complication in insulin-treated diabetes. The fear of hypoglycaemia discourages diabetic subjects from the attempt to maintain tight glycemic control, which in turn leads to increased…
- Trial name
- NCT01178476
- Testing
- Hyposafe Hypoglycaemia alarm device
- Where
- Denmark
- Sponsor
- UNEEG Medical A/S